Perioperative Imfinzi Plus Neoadjuvant EV Showed Statistically Significant and Clinically Meaningful Improvements in Event-Free Survival and Overall Survival in Muscle-Invasive Bladder Cancer in the Phase III VOLGA Trial
May 15, 2026
May 15, 2026
WILMINGTON, Delaware, May 15 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Perioperative IMFINZI(R) (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
Perioperative IMFINZI plus IMJUDO(R) (tremelimumab-actl) and neoadjuvant EV showed a statistically significan . . .
* * *
Perioperative IMFINZI(R) (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
Perioperative IMFINZI plus IMJUDO(R) (tremelimumab-actl) and neoadjuvant EV showed a statistically significan . . .